admabiologics.com (ADMA) - מזומנים למניה

ADMA Biologics aims for dominance in the plasma-derived therapies segment by expanding its collection center network to drive profit growth. This chart of cash per share, where the parameter has stabilized at 0.55, links market value to the business's actual coverage. In-house immunoglobulin manufacturing plants ensure stability, while stringent FDA oversight and complex facility certification create high barriers to entry.
פילוחים אנליטיים של חברת ADMA Biologics

Proprietary plasma collection centers and FDA protection provide ADMA Biologics (ADMA) with high margins, transforming liquidity into a tool for strategic development. This metric measures the actual dollar amount of cash per share, allowing investors to assess the business's margin of safety and the risk of underperformance due to excess cash by analyzing fluctuations in cash per share.